未登录

C

Christian Tovar

roche holding usa

H指数:21

被引数:4,791

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mouse IL-2/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus

JOURNAL OF IMMUNOLOGY

IF3.4

2021-07-0115

OA

Thermal oxidative and ultraviolet ageing behaviour of nano-montmorillonite modified bitumen

纳米蒙脱土改性沥青的热氧和紫外老化行为

ROAD MATERIALS AND PAVEMENT DESIGN

IF3

2019-06-0451

PREAI

Combination of MDM2 antagonists with RAS pathway inhibitors in colorectal cancer

EUROPEAN JOURNAL OF CANCER

IF7.1

2014-11-010

PREAI

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence Implications for therapy

IF3.4

2014-10-3128

OAAI

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

IF3.4

2014-10-2775

PREAI

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2014-08-0154

PREAI

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

CLINICAL CANCER RESEARCH

IF10.2

2014-07-1467

OAAI

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2014-01-0785

OA

Antitumor activity of the MDM2 antagonist RG7388.

MOLECULAR CANCER THERAPEUTICS

IF5.5

2013-11-015

PRE

Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2013-08-14647

OAAI

Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2013-07-16532

PREAI

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

CANCER RESEARCH

IF16.6

2013-04-15275

OA

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2013-04-04381

OA

Discovery of a Highly Potent, Orally Active Mitosis/Angiogenesis Inhibitor R1530 for the Treatment of Solid Tumors

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2013-01-2223

OA

ATSP-7041, a Dual MDM2 and MDMX Targeting Stapled A-helical Peptide Exhibits Potent in Vitro and in Vivo Efficacy in Xenograft Models of Human Cancer

EUROPEAN JOURNAL OF CANCER

IF7.1

2012-11-013

PREAI

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2012-06-28220

OA

Antitumor activity of the MDM2 antagonist, RG7112

CANCER RESEARCH

IF16.6

2012-04-010

PRE

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

MOLECULAR CANCER

IF33.9

2011-05-0341

OAAI

In vitro and in vivo activity of R547:: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

MOLECULAR CANCER THERAPEUTICS

IF5.5

2006-11-22118

OAAI

Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2006-07-11687

OAAI